Patent ID: 8877764
Filing Date: 2014-11-04
Classification: A61K,A61P

Abstract:
1. A method of treating patients suffering from cancer selected from the group consisting of Central nervous system tumours selected from the group consisting of: Astrocytoma, glioblastoma, meningeoma, neurinoma, schwannoma, ependymoma, hypophysoma, oligodendroglioma and medulloblastoma; Ovarian cancers selected from the group consisting of: Epithelial tumours, stroma tumours, germ cell tumours and undifferentiated tumours; Prostate cancers selected from the group consisting of: AC, small cell and SCC; said cancers harbouring a mutation of the EGFR gene in the tumour, wherein the EGFR mutation is an activating mutation selected from the group of mutations identified in table 1 under No. 1 to 29, 57 to 65, 73, 75, 76, 77, 79 and 80-91, wherein the cancer shows resistance or acquired resistance to treatment with reversible EGFR and HER2 inhibitors or to other irreversible inhibitors selected from CI-1033, EKB-569, HKI-272 or HKI-357, said method consisting of administering a therapeutically effective amount of the single irreversible EGFR inhibitor BIBW 2992 (1) to a patient in need thereof, optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery.